Tribute Pharmaceuticals Canada Inc  

(Public, OTCMKTS:TBUFF)   Watch this stock  
Find more results for otc:slxcf
0.580
-0.015 (-2.52%)
Apr 24 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.58 - 0.60
52 week 0.32 - 0.75
Open 0.60
Vol / Avg. 19,000.00/91,395.00
Mkt cap 29.92M
P/E     -
Div/yield     -
EPS -0.15
Shares 51.58M
Beta 1.61
Inst. own 12%
Mar 31, 2014
Q4 2013 Tribute Pharmaceuticals Canada Inc Earnings Conference Call - Webcast
Mar 31, 2014
Q4 2013 Tribute Pharmaceuticals Canada Inc Earnings Release
  

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin -74.24% -27.13%
Operating margin -50.30% -35.99%
EBITD margin - -28.84%
Return on average assets -50.70% -16.73%
Return on average equity -109.68% -26.68%
Employees 40 -
CDP Score - -

Address

151 Steeles Ave. E.
MILTON, ON L9T 1Y1
Canada
+1-905-8761118 (Phone)

Website links

Description

Tribute Pharmaceuticals Canada Inc., formerly Stellar Pharmaceuticals Inc., is a Canadian pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada. The Company targets several therapeutic areas in Canada but has a particular interest in products for the treatment of pain, urology, dermatology and endocrinology/cardiology. It also sells Uracyst and NeoVisc internationally through a number of strategic partnerships. On December 1, 2011, it acquired 100% of Tribute Pharmaceuticals Canada Ltd. and Tribute Pharma Canada Inc. As of December 31, 2011, its portfolio of assets includes nine products: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, and MycoVa. It has licensed BladderChek for the Canadian market from Inverness Medical Innovations North America, Inc. It eveloped Uracyst, a sterile 2 % sodium chondroitin sulfate solution available in a 20 milliliter vial.

Officers and directors

Arnold Tenney Chairman of the Board
Age: 70
Robert Harris President, Chief Executive Officer, Director
Age: 57
Scott Langille Chief Financial Officer, Director
Age: 56
Janice M. Clarke Vice President - Finance and Administration
Age: 52
Steven H. Goldman Independent Director
Age: 57
John M. Gregory Independent Director
Age: 60
John J. Kime Independent Director
Age: 70
Francis Martin Thrasher Independent Director
Age: 61